EcoDrugPlus

Bradykinin Receptor B2

Ensembl ID : ENSPEMG00000027528
Gene Symbol: BDKRB2
3 Cross references
356 Possible Orthologues:

Bradykinin Receptor, Beta 1

Ensembl ID : ENSPEMG00000017065
Gene Symbol: BDKRB1
1 Cross references
147 Possible Orthologues:

Butyrylcholinesterase

Ensembl ID : ENSPEMG00000009079
Gene Symbol: BCHE
3 Cross references
130 Possible Orthologues:

Calcitonin Receptor-Like

Ensembl ID : ENSPEMG00000004539
Gene Symbol: CALCRL
1 Cross references
147 Possible Orthologues:

Calcium Channel, Voltage-Dependent, L Type, Alpha 1c Subunit

Ensembl ID : ENSPEMG00000019427
Gene Symbol: CACNA1C
1 Cross references
211 Possible Orthologues:

Calcium Channel, Voltage-Dependent, L Type, Alpha 1d Subunit

Ensembl ID : ENSPEMG00000013031
Gene Symbol: CACNA1D
1 Cross references
281 Possible Orthologues:

Calcium Channel, Voltage-Dependent, N Type, Alpha 1b Subunit

Ensembl ID : ENSPEMG00000007882
Gene Symbol: CACNA1B
1 Cross references
283 Possible Orthologues:

Calcium Channel, Voltage-Dependent, R Type, Alpha 1e Subunit

Ensembl ID : ENSPEMG00000012746
Gene Symbol: CACNA1E
1 Cross references
294 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Alpha 2/delta Subunit 2

Ensembl ID : ENSPEMG00000009867
Gene Symbol: CACNA2D2
1 Cross references
272 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Alpha 2/delta Subunit 4

Ensembl ID : ENSPEMG00000019929
Gene Symbol: CACNA2D4
1 Cross references
317 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Alpha2/delta Subunit 1

Ensembl ID : ENSPEMG00000019975
Gene Symbol: CACNA2D1
1 Cross references
285 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 6

Ensembl ID : ENSPEMG00000008282
Gene Symbol: CACNG6
1 Cross references
248 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).